Detalhe da pesquisa
1.
Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma.
Blood
; 136(22): 2513-2523, 2020 11 26.
Artigo
Inglês
| MEDLINE | ID: mdl-32735641
2.
Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma.
Br J Haematol
; 186(4): 549-560, 2019 08.
Artigo
Inglês
| MEDLINE | ID: mdl-31124580
3.
A phase 1 clinical trial evaluating marizomib, pomalidomide and low-dose dexamethasone in relapsed and refractory multiple myeloma (NPI-0052-107): final study results.
Br J Haematol
; 180(1): 41-51, 2018 01.
Artigo
Inglês
| MEDLINE | ID: mdl-29076150
4.
Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 Part 1.
Blood
; 127(22): 2693-700, 2016 06 02.
Artigo
Inglês
| MEDLINE | ID: mdl-27009059
5.
Tibiofemoral Contact Mechanics With Horizontal Cleavage Tears and Treatment of the Lateral Meniscus in the Human Knee: An In Vitro Cadaver Study.
Clin Orthop Relat Res
; 476(11): 2262-2270, 2018 11.
Artigo
Inglês
| MEDLINE | ID: mdl-30188343
6.
Arthroscopic treatment successfully treats posterior elbow impingement in an athletic population.
Knee Surg Sports Traumatol Arthrosc
; 26(1): 306-311, 2018 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-28534159
7.
Initial genome sequencing and analysis of multiple myeloma.
Nature
; 471(7339): 467-72, 2011 Mar 24.
Artigo
Inglês
| MEDLINE | ID: mdl-21430775
8.
Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma.
Blood
; 124(7): 1047-55, 2014 Aug 14.
Artigo
Inglês
| MEDLINE | ID: mdl-24904120
9.
Bendamustine, lenalidomide, and dexamethasone (BRD) is highly effective with durable responses in relapsed multiple myeloma.
Am J Hematol
; 90(12): 1106-10, 2015 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-26331432
10.
A standardized educational program to improve peripheral vascular access outcomes in the emergency department: A quasi-experimental pre-post trial.
J Vasc Access
; : 11297298231219776, 2024 Jan 05.
Artigo
Inglês
| MEDLINE | ID: mdl-38183178
11.
Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial.
Blood
; 118(3): 535-43, 2011 Jul 21.
Artigo
Inglês
| MEDLINE | ID: mdl-21596852
12.
Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: a Phase I Multiple Myeloma Research Consortium study.
Br J Haematol
; 158(4): 472-80, 2012 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-22640031
13.
Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial.
Lancet Haematol
; 8(1): e45-e54, 2021 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-33357482
14.
Indatuximab ravtansine plus dexamethasone with lenalidomide or pomalidomide in relapsed or refractory multiple myeloma: a multicentre, phase 1/2a study.
Lancet Haematol
; 8(11): e794-e807, 2021 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-34529955
15.
Regulatory T-cell depletion in the setting of autologous stem cell transplantation for multiple myeloma: pilot study.
J Immunother Cancer
; 8(1)2020 01.
Artigo
Inglês
| MEDLINE | ID: mdl-31940591
16.
Indatuximab Ravtansine (BT062) Monotherapy in Patients With Relapsed and/or Refractory Multiple Myeloma.
Clin Lymphoma Myeloma Leuk
; 19(6): 372-380, 2019 06.
Artigo
Inglês
| MEDLINE | ID: mdl-30930134
17.
Combining carfilzomib and panobinostat to treat relapsed/refractory multiple myeloma: results of a Multiple Myeloma Research Consortium Phase I Study.
Blood Cancer J
; 9(1): 3, 2019 01 04.
Artigo
Inglês
| MEDLINE | ID: mdl-30610196
18.
Expression of functional folate receptors in multiple myeloma.
Leuk Lymphoma
; 59(12): 2982-2989, 2018 12.
Artigo
Inglês
| MEDLINE | ID: mdl-29616859
19.
Prognostic Validation of SKY92 and Its Combination With ISS in an Independent Cohort of Patients With Multiple Myeloma.
Clin Lymphoma Myeloma Leuk
; 17(9): 555-562, 2017 09.
Artigo
Inglês
| MEDLINE | ID: mdl-28735890
20.
Phase II randomized trial of bevacizumab versus bevacizumab and thalidomide for relapsed/refractory multiple myeloma: a California Cancer Consortium trial.
Br J Haematol
; 154(4): 533-5, 2011 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-21517811